{"ticker": {"uuid": "7963bbd5-fe62-4802-839d-f37566903b1e", "symbol": "CTSO", "name": "Cytosorbents Crp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR\u2019s Tom Kerr, CFA", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/otc-markets-life-sciences-investor-100200724.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-07-08T10:02:00+00:00", "published_display": "08 Jul 2026 10:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure", "summary": "CytoSorbents (NASDAQ: CTSO) has received a notice from Nasdaq for non-compliance with the $35 million Market Value of Listed Securities requirement. The company now has 180 calendar days, until December 28, 2026, to regain compliance by maintaining a market value at or above $35 ", "url": "https://www.stocktitan.net/sec-filings/CTSO/8-k-cytosorbents-corp-reports-material-event-279b13e7a9c5.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:01", "published_display": "06 Jul 2026 20:12", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "CytoSorbents (CTSO) received a notice from Nasdaq on June 29, 2026, indicating non-compliance with Listing Rule 5550(b)(2) because its market value of listed securities fell below the $35 million minimum. The company has 180 days, until December 28, 2026, to regain compliance by ", "url": "https://www.tradingview.com/news/tradingview:8d4aa059d9e46:0-cytosorbents-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-07-06T20:12:01", "published_display": "06 Jul 2026 20:12", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO - Cytosorbents Corp Options", "summary": "This page provides a detailed financial overview of Cytosorbents Corp (CTSO), including its last trading close, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider and institutional ownership percentages, and price pe", "url": "https://finviz.com/stock?t=CTSO&ta=1&p=d&ty=oc&r=m6", "source_name": "Finviz", "published_at": "2026-07-04T18:39:18", "published_display": "04 Jul 2026 18:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO | Cytosorbents Corp. Executive Compensation", "summary": "This article provides an overview of Cytosorbents Corp. (CTSO) focusing on executive compensation, insider trading, institutional holdings, government contracts, and patent information. It highlights specific patent grants related to medical technologies and lists federal governm", "url": "https://www.quiverquant.com/stock/CTSO/executive-compensation/", "source_name": "Quiver Quantitative", "published_at": "2026-06-27T22:09:17", "published_display": "27 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corporation (CTSO) Presents at Life Sciences Virtual Investor Forum - Slideshow", "summary": "Cytosorbents Corporation (CTSO) delivered a presentation at the Life Sciences Virtual Investor Forum. This article is a reproduction of the slide deck presented by the company at the event. The content was prepared by Seeking Alpha's transcripts team.", "url": "https://seekingalpha.com/article/4918277-cytosorbents-corporation-ctso-presents-at-life-sciences-virtual-investor-forum-slideshow", "source_name": "Seeking Alpha", "published_at": "2026-06-27T19:13:00", "published_display": "27 Jun 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] Cytosorbents Corp SEC Filing", "summary": "This article announces an ARS SEC filing for Cytosorbents Corp (CTSO), noting a low impact and neutral sentiment. The filing was accepted by the SEC on June 25, 2026, and is available as a PDF. The company's stock overview, recent news, and other SEC filings are also provided.", "url": "https://www.stocktitan.net/sec-filings/CTSO/ars-cytosorbents-corp-sec-filing-6dd24f13513c.html", "source_name": "Stock Titan", "published_at": "2026-06-25T22:09:17", "published_display": "25 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing", "summary": "CytoSorbents (NASDAQ: CTSO) is seeking shareholder approval for a reverse stock split at its upcoming virtual annual meeting on August 13, 2026. This move, with a proposed ratio between 1-for-5 and 1-for-20, is primarily aimed at raising the stock's per-share price to regain comp", "url": "https://www.stocktitan.net/sec-filings/CTSO/def-14a-cytosorbents-corp-definitive-proxy-statement-1bb4c67ca51c.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:39:40", "published_display": "25 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals", "summary": "CytoSorbents (NASDAQ: CTSO) has detailed its plans for upcoming FDA pre-submission meetings in August 2026 regarding its DrugSorb-ATR device for ticagrelor and DOAC removal, targeting late 2026 or early 2027 De Novo submissions. The company reported $37.1 million in 2025 sales fo", "url": "https://www.stocktitan.net/sec-filings/CTSO/8-k-cytosorbents-corp-reports-material-event-81494d958610.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:11:36", "published_display": "25 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs", "summary": "CytoSorbents (CTSO) has announced two FDA pre-submission meetings in August 2026 to advance its ticagrelor and DOAC programs. The company plans a new De Novo submission for ticagrelor removal after the FDA requested additional mechanistic data and will hold a separate meeting for", "url": "https://www.tradingview.com/news/tradingview:1d24fa6d4ffb0:0-cytosorbents-schedules-two-fda-pre-submission-meetings-for-ticagrelor-and-doac-programs/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:36", "published_display": "25 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Cytosorbents Corp (CTSO), highlighting its current valuation score of 8.74, ranking it 65th in the Healthcare Equipment & Supplies industry. It notes the company's P/E ratio is -2.47, a significant deviation from its recent high and l", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T08:10:42", "published_display": "23 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Spends US$105k Buying More Shares In Cytosorbents", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYlcxMThlQVQtWkVRd09McEpJbzMwdWgwWXdWaUFGZGROcUdzTUYwb1pXQlNIdmFncURnVkdpWnFETzlmdHVUeDFiaE1pTm5TcTY1WlpDSEM5NGZTWldsa0xMMnJ2dEcyN2N6TE9wQU02WWhXaktRbnRUaXVRSGxMd19hMXVNWHRLbmdva3NYOTM2Nk82UWtEMEx1cm04OUNsYVp0UG96TGFVWklQUnE3Q3cyVEN1UnZaVDF5OXNvb3AzZEhtTV9nQ9IBzgFBVV95cUxOQWt5YnBlSUdJWTlEOXByLVRaYkY3ZWNkM180aF9JbnJ5NEZ0eUV6bDB3WVNSYUowaEJ5ejVwY0hBUVJiYTNhTWxuLW1ncGNGUmhfQXctWlVIU3FKZmNXVmdsTDBmcUc4bGJCRVdGalJWVnBvbi1YQzNNT2pzdjk4cG50NmduXzlyazhTNDJqLXhPeHhYeEdKSlhoOHkxZWlRUnhrVUluS3lYSGx0Mm9ISTVCd1NxZGQzanVSS2dCVDRXVUwyRzEtWGtvLW4zdw?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cytosorbents Corp (CTSO), noting its current price momentum score of 6.32 and suggesting suitability for range-bound swing trading between resistance at 0.57 and support at 0.34. Based on various technical indicators and moving averag", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/technical", "source_name": "TradingKey", "published_at": "2026-06-18T17:40:50", "published_display": "18 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026", "summary": "CytoSorbents Corporation announced that its CEO, Dr. Phillip Chan, will present at the Life Sciences Forum on June 24, 2026, to provide an overview and update on the company. Following the presentation, Dr. Chan and CFO Peter Mariani will participate in a Q&A session. The company", "url": "https://finance.yahoo.com/healthcare/articles/cytosorbents-present-life-sciences-forum-124600078.html", "source_name": "Market source", "published_at": "2026-06-18T13:10:51", "published_display": "18 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Institutional Confidence", "summary": "Cytosorbents Corp (CTSO) has an institutional shareholding score of 3.00, placing it 132nd in its industry, with 25.84% institutional ownership, a 10.95% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.16% of outstanding shares. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T07:10:44", "published_display": "18 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Cytosorbents Corp (CTSO), detailing its regional revenue contributions. As of the latest update on April 6, the company's revenue is primarily generated from \"All Other\" regions (67.62%) and Germany (31.71%), with a small portion from", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:51", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cytosorbents Corp (CTSO), highlighting its current earnings forecast score of 7.00 and ranking in the Healthcare Equipment & Supplies industry. It details analyst ratings, price targets, and expected EPS and revenue figures. The fore", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:52", "published_display": "17 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) Drops 9% as Shares Test Key Support at $0.45 - Dividend Arbitrage", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOMmFrdEVNWG1lLVRrNUJXaEM0eXUycWt5R0U1SWx4TXNSYU4tX2RNOTJJVU1yQUl3M2NnWWNjbVZuQmliaHpQNWtLWkZ0ZF9FbTNWc25mTUVWcUg5c3dudkRSelZnYUVDZ1hZWHNTWG9PRDgydy1haEtfZ0lGVlNXS0RvaDM0dndxQ3ZKaV9VbXlXOEk2T0JwanNtUEx5d3dDVXZoRUlkWnBvSER0?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents CFO Peter Mariani buys $44,000 in stock", "summary": "Cytosorbents Corp's CFO, Peter Mariani, purchased 100,000 shares of company stock for $44,000, acquiring them at a weighted average price of $0.44 per share. This insider transaction occurred when the stock was near its 52-week low and analysts anticipate the company will become ", "url": "https://www.investing.com/news/insider-trading-news/cytosorbents-cfo-peter-mariani-buys-44000-in-stock-93CH-4744382", "source_name": "Investing.com", "published_at": "2026-06-17T06:11:11", "published_display": "17 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) CFO Peter Mariani buys 100,000 shares in open market", "summary": "Cytosorbents Corp's CFO, Peter J. Mariani, purchased 100,000 shares of common stock at a weighted average price of $0.44 per share on June 15, 2026, increasing his direct holdings to 638,113 shares. This open-market transaction signals a positive sentiment from the insider. His h", "url": "https://www.stocktitan.net/sec-filings/CTSO/form-4-cytosorbents-corp-insider-trading-activity-a82f2eeaec29.html", "source_name": "Stock Titan", "published_at": "2026-06-16T10:39:15", "published_display": "16 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cytosorbents (CTSO) CEO boosts stake with 261,469-share open-market buy", "summary": "Cytosorbents Corp (CTSO) CEO Phillip P. Chan increased his direct holdings by purchasing 261,469 shares in open-market transactions on June 12 and June 15, 2026. He acquired shares at weighted average prices of $0.40 and $0.43 respectively, totaling approximately $104,898. Follow", "url": "https://www.stocktitan.net/sec-filings/CTSO/form-4-cytosorbents-corp-insider-trading-activity-a060ffa02ea2.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:39:15", "published_display": "15 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents CEO Phillip Chan buys $104,897 in company stock", "summary": "Cytosorbents Corp CEO Phillip P. Chan recently purchased $104,897 worth of company stock through open market transactions on June 12 and June 15, 2026. The purchases occurred while the stock was trading near its 52-week low and is considered undervalued by InvestingPro analysis. ", "url": "https://www.investing.com/news/insider-trading-news/cytosorbents-ceo-phillip-chan-buys-104897-in-company-stock-93CH-4743520", "source_name": "Investing.com", "published_at": "2026-06-15T22:39:15", "published_display": "15 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Cytosorbents Corp (CTSO), noting its current score of 6.45, which ranks it 154 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's weak financial status and average operating efficiency. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/financial-health", "source_name": "TradingKey", "published_at": "2026-06-15T22:12:08", "published_display": "15 Jun 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near?", "summary": "Cytosorbents Corporation (NASDAQ:CTSO) is projected to reach breakeven by 2027, according to analysts, after incurring a final loss in 2026. This would require an average annual growth rate of 77%. The company currently has a high debt-to-equity ratio of over 2x, which poses a ri", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-ctso/cytosorbents/news/cytosorbents-corporation-nasdaqctso-is-breakeven-near-1", "source_name": "Simply Wall Street", "published_at": "2026-06-12T10:40:31", "published_display": "12 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents (NASDAQ: CTSO) asks shareholders to OK 1-for-5\u20131-for-20 reverse split", "summary": "CytoSorbents (NASDAQ: CTSO) is seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-20 at its upcoming Annual Meeting on August 13, 2026. This measure is primarily intended to help the company meet Nasdaq's minimum bid price requirement of $", "url": "https://www.stocktitan.net/sec-filings/CTSO/pre-14a-cytosorbents-corp-preliminary-proxy-statement-f7532ebc5865.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:57", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corp stock (US23283M1018): Q1 miss keeps focus on growth and cash runway", "summary": "CytoSorbents Corp reported weaker than expected Q1 2026 revenue of $8.9 million and a larger loss per share of -$0.05, missing analyst estimates. This performance keeps the focus on the company's growth trajectory, its path to profitability, and the demand for its blood purificat", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cytosorbents-corp-stock-us23283m1018-q1-miss-keeps-focus-on-growth-and/69507553", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T12:39:32", "published_display": "09 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) Edges Higher on Modest Volume, Testing Key Resistance at $0.49 - ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNbG5ReWZ1THhYWFV3c1pjMlkwMGpoUklmekNnejlFY0JGVGFkODZOMGsyVGxHMzFtN1hEMUw3RkZRVDVpc3ljV0dLYmlQQVJhYnlsaXp6dmplbm1DUXFyQnN0Y29RSlNxc2pwZzEtUkZuQVNFNll2dF83WkxsVDRCSTU5MEVkM0dTQmxrQ24wQ1k1ZVZ0Q3duSk03aHlRdC04WjE4bXg4dFg0bnF3YVNmOUVZdU54MlotS0NFUWhsT0ZSUm8?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Cytosorbents Corp (CTSO), indicating a \"Strong Sell\" consensus based on various technical indicators and moving averages. The analysis highlights that CTSO is trading below its key moving averages and identif", "url": "https://intellectia.ai/en/stock/CTSO/technical", "source_name": "Intellectia AI", "published_at": "2026-06-07T03:40:36", "published_display": "07 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-l", "summary": "CytoSorbents Corp (CTSO) shares on Nasdaq are trading at a low nominal level of USD 0.49, despite several Wall Street analysts maintaining significantly higher 12-month price targets, with a consensus of USD 5.38. The company, focused on blood purification therapies, continues to", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cytosorbents-corp-stock-us23283m1018-analyst-sentiment-and-low-share/69458659", "source_name": "Ad Hoc News", "published_at": "2026-06-01T00:51:48", "published_display": "01 Jun 2026 00:51", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO - Cytosorbents Corp Stock Price and Quote", "summary": "This article provides a comprehensive overview of Cytosorbents Corp (CTSO) stock, including its current price, financial metrics, and recent news. It details key financial data such as market cap, income, sales, and various ratios, alongside performance indicators and analyst rat", "url": "https://finviz.com/stock?t=CTSO", "source_name": "Finviz", "published_at": "2026-05-29T22:12:08", "published_display": "29 May 2026 22:12", "sentiment": "negative", "sentiment_pct": 31, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corp stock (US23283M1018): Nasdaq price action and valuation metrics in focus", "summary": "CytoSorbents Corp (CTSO) shares on the Nasdaq Capital Market continue to trade at low single-digit levels, attracting risk-tolerant investors interested in medical technology stocks. The company, which focuses on blood purification technologies, is currently assessed using revenu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cytosorbents-corp-stock-us23283m1018-nasdaq-price-action-and-valuation/69437595", "source_name": "Ad Hoc News", "published_at": "2026-05-29T01:39:16", "published_display": "29 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO: CytoSorbents Reports 1st Quarter Financial and Operating Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ctso-cytosorbents-reports-1st-quarter-170300618.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-05-21T17:03:00+00:00", "published_display": "21 May 2026 17:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cytosorbents Earnings Call Balances Progress and Pressure", "summary": "Cytosorbents' Q1 2026 earnings call revealed a combination of cautious optimism and ongoing challenges. The company reported modest revenue growth, driven by international sales outside Germany, alongside strong margins. However, it also faced headwinds from FX losses, regulatory", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CTSO/pressreleases/2053858/cytosorbents-earnings-call-balances-progress-and-pressure/", "source_name": "The Globe and Mail", "published_at": "2026-05-20T23:10:47", "published_display": "20 May 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cytosorbents-corp-ctso-q1-2026-050246425.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T05:02:46+00:00", "published_display": "14 May 2026 05:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: CytoSorbents Q1 2026 Earnings Conference Call", "summary": "", "url": "https://finance.yahoo.com/news/transcript-cytosorbents-q1-2026-earnings-213610053.html", "source_name": "Benzinga", "published_at": "2026-05-13T21:36:10+00:00", "published_display": "13 May 2026 21:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/cytosorbents-q1-earnings-snapshot-200357687.html", "source_name": "Associated Press", "published_at": "2026-05-13T20:03:57+00:00", "published_display": "13 May 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPYzRvS014bC04bUxUc0xvYVNMYTJrWGhXUlhvYW92VklUcHpHalF0akc3allMZmxPWFRSNE02OWRlQmZCOHQ5ei1UY2xMSFdaMUROMHZyUVozQWdSVjd3TU52QTgtQVpLOUJXUFoxNTJwbDBvV1c3cTFJcGJKY2xoTi13VU1MNmFFTzc4QkhqU3VNZzJMUWV2YUtXaTNOX2xGNTR2cnZaWHl4V05iZ0xCUFFGQnpNNXNBaURhaWJtSFJoMkhNQWZFRE1WbkV0enlabHp4N3V4WDQ5a2RKMWpOa3h6S0NHc0xoUy1qbVFDMGNLLThh?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cytosorbents-report-first-quarter-2026-110000553.html", "source_name": "PR Newswire", "published_at": "2026-04-30T11:00:00+00:00", "published_display": "30 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQeTRqQ0k5TGJqUGdraFkzc0p1YWlQRUtSNFh1NFhhZjFJQ3ZpbV9TcHVObEduRlhKNUpzSGRLY1gwWGNHOTFmNktqeDRUTmp3SHZwMUVyMXVpRm5NeTlMNWhuSlFDcTFRYmN0Ykk4VEs3M3ZBalRPVHJWenhLeVVObERDTHV2NmZ2UDRxa3VQSlZKTVNTVUVtZW43b2w?oc=5", "source_name": "Market source", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1yQmtncHVOb082QkU0Z2hJVGpVNUlpTFpkN1drb3Q1aDBXNVdvMGxBUUZzd3ozNy1NM3diVTVjRW41cWlQNllPZ1E0VVdXWVZKZVRz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:06:27+00:00", "published_display": "24 Apr 2025 22:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corporation Announces Rights Offering Details and Stockholder Benefits", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPRDdtajNsUjlsT3FybjN5MFA2T1JkMHdkVWRXMnQ4RE9SMzZ3SEF6TWZENzFsdVBsM1NRT0V0NkNJX19TMXVDRnlQSHlYUFdvTXZOdHBzWXdYQVBmb3Y0WHhmR0doLVdPM2hSWU1iZU9odlFQblVibWVJcDRnNDU3ajFnbElSY2xjZ0REV0o3Q3hyVFJmQTlKVHR4Z2tGUnEyU0JzWjJwQ0ZYTWNfMkNHRUcyTVd3eWM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-12-09T08:00:00+00:00", "published_display": "09 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Cytosorbents (CTSO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1BNmNKaUFJUkIwVERSVXNHRUNfN2hTQk41SmhYQjg2eG9ybGxZb2R0U3BnMmFkS2ZEXzNxUHIzczV0ZFlLTl9LYTJEQXJJalI3STNOMDVnVTRDUUlYU0JaekZwZ0pPUEhQWEJfNEFLYjJVa1U2Wl9BSA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-09-03T11:11:59+00:00", "published_display": "03 Sep 2022 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR\u2019s Tom Kerr, CFA", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/otc-markets-life-sciences-investor-100200724.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-07-08T10:02:00+00:00", "published_display": "08 Jul 2026 10:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure", "summary": "CytoSorbents (NASDAQ: CTSO) has received a notice from Nasdaq for non-compliance with the $35 million Market Value of Listed Securities requirement. The company now has 180 calendar days, until December 28, 2026, to regain compliance by maintaining a market value at or above $35 ", "url": "https://www.stocktitan.net/sec-filings/CTSO/8-k-cytosorbents-corp-reports-material-event-279b13e7a9c5.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:01", "published_display": "06 Jul 2026 20:12", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "CytoSorbents (CTSO) received a notice from Nasdaq on June 29, 2026, indicating non-compliance with Listing Rule 5550(b)(2) because its market value of listed securities fell below the $35 million minimum. The company has 180 days, until December 28, 2026, to regain compliance by ", "url": "https://www.tradingview.com/news/tradingview:8d4aa059d9e46:0-cytosorbents-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-07-06T20:12:01", "published_display": "06 Jul 2026 20:12", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO - Cytosorbents Corp Options", "summary": "This page provides a detailed financial overview of Cytosorbents Corp (CTSO), including its last trading close, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider and institutional ownership percentages, and price pe", "url": "https://finviz.com/stock?t=CTSO&ta=1&p=d&ty=oc&r=m6", "source_name": "Finviz", "published_at": "2026-07-04T18:39:18", "published_display": "04 Jul 2026 18:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO | Cytosorbents Corp. Executive Compensation", "summary": "This article provides an overview of Cytosorbents Corp. (CTSO) focusing on executive compensation, insider trading, institutional holdings, government contracts, and patent information. It highlights specific patent grants related to medical technologies and lists federal governm", "url": "https://www.quiverquant.com/stock/CTSO/executive-compensation/", "source_name": "Quiver Quantitative", "published_at": "2026-06-27T22:09:17", "published_display": "27 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corporation (CTSO) Presents at Life Sciences Virtual Investor Forum - Slideshow", "summary": "Cytosorbents Corporation (CTSO) delivered a presentation at the Life Sciences Virtual Investor Forum. This article is a reproduction of the slide deck presented by the company at the event. The content was prepared by Seeking Alpha's transcripts team.", "url": "https://seekingalpha.com/article/4918277-cytosorbents-corporation-ctso-presents-at-life-sciences-virtual-investor-forum-slideshow", "source_name": "Seeking Alpha", "published_at": "2026-06-27T19:13:00", "published_display": "27 Jun 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] Cytosorbents Corp SEC Filing", "summary": "This article announces an ARS SEC filing for Cytosorbents Corp (CTSO), noting a low impact and neutral sentiment. The filing was accepted by the SEC on June 25, 2026, and is available as a PDF. The company's stock overview, recent news, and other SEC filings are also provided.", "url": "https://www.stocktitan.net/sec-filings/CTSO/ars-cytosorbents-corp-sec-filing-6dd24f13513c.html", "source_name": "Stock Titan", "published_at": "2026-06-25T22:09:17", "published_display": "25 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing", "summary": "CytoSorbents (NASDAQ: CTSO) is seeking shareholder approval for a reverse stock split at its upcoming virtual annual meeting on August 13, 2026. This move, with a proposed ratio between 1-for-5 and 1-for-20, is primarily aimed at raising the stock's per-share price to regain comp", "url": "https://www.stocktitan.net/sec-filings/CTSO/def-14a-cytosorbents-corp-definitive-proxy-statement-1bb4c67ca51c.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:39:40", "published_display": "25 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals", "summary": "CytoSorbents (NASDAQ: CTSO) has detailed its plans for upcoming FDA pre-submission meetings in August 2026 regarding its DrugSorb-ATR device for ticagrelor and DOAC removal, targeting late 2026 or early 2027 De Novo submissions. The company reported $37.1 million in 2025 sales fo", "url": "https://www.stocktitan.net/sec-filings/CTSO/8-k-cytosorbents-corp-reports-material-event-81494d958610.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:11:36", "published_display": "25 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs", "summary": "CytoSorbents (CTSO) has announced two FDA pre-submission meetings in August 2026 to advance its ticagrelor and DOAC programs. The company plans a new De Novo submission for ticagrelor removal after the FDA requested additional mechanistic data and will hold a separate meeting for", "url": "https://www.tradingview.com/news/tradingview:1d24fa6d4ffb0:0-cytosorbents-schedules-two-fda-pre-submission-meetings-for-ticagrelor-and-doac-programs/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:36", "published_display": "25 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Cytosorbents Corp (CTSO), highlighting its current valuation score of 8.74, ranking it 65th in the Healthcare Equipment & Supplies industry. It notes the company's P/E ratio is -2.47, a significant deviation from its recent high and l", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T08:10:42", "published_display": "23 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Spends US$105k Buying More Shares In Cytosorbents", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cytosorbents Corp (CTSO), noting its current price momentum score of 6.32 and suggesting suitability for range-bound swing trading between resistance at 0.57 and support at 0.34. Based on various technical indicators and moving averag", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/technical", "source_name": "TradingKey", "published_at": "2026-06-18T17:40:50", "published_display": "18 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026", "summary": "CytoSorbents Corporation announced that its CEO, Dr. Phillip Chan, will present at the Life Sciences Forum on June 24, 2026, to provide an overview and update on the company. Following the presentation, Dr. Chan and CFO Peter Mariani will participate in a Q&A session. The company", "url": "https://finance.yahoo.com/healthcare/articles/cytosorbents-present-life-sciences-forum-124600078.html", "source_name": "Market source", "published_at": "2026-06-18T13:10:51", "published_display": "18 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Institutional Confidence", "summary": "Cytosorbents Corp (CTSO) has an institutional shareholding score of 3.00, placing it 132nd in its industry, with 25.84% institutional ownership, a 10.95% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.16% of outstanding shares. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T07:10:44", "published_display": "18 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Cytosorbents Corp (CTSO), detailing its regional revenue contributions. As of the latest update on April 6, the company's revenue is primarily generated from \"All Other\" regions (67.62%) and Germany (31.71%), with a small portion from", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:51", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cytosorbents Corp (CTSO), highlighting its current earnings forecast score of 7.00 and ranking in the Healthcare Equipment & Supplies industry. It details analyst ratings, price targets, and expected EPS and revenue figures. The fore", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:52", "published_display": "17 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) Drops 9% as Shares Test Key Support at $0.45 - Dividend Arbitrage", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOMmFrdEVNWG1lLVRrNUJXaEM0eXUycWt5R0U1SWx4TXNSYU4tX2RNOTJJVU1yQUl3M2NnWWNjbVZuQmliaHpQNWtLWkZ0ZF9FbTNWc25mTUVWcUg5c3dudkRSelZnYUVDZ1hZWHNTWG9PRDgydy1haEtfZ0lGVlNXS0RvaDM0dndxQ3ZKaV9VbXlXOEk2T0JwanNtUEx5d3dDVXZoRUlkWnBvSER0?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents CFO Peter Mariani buys $44,000 in stock", "summary": "Cytosorbents Corp's CFO, Peter Mariani, purchased 100,000 shares of company stock for $44,000, acquiring them at a weighted average price of $0.44 per share. This insider transaction occurred when the stock was near its 52-week low and analysts anticipate the company will become ", "url": "https://www.investing.com/news/insider-trading-news/cytosorbents-cfo-peter-mariani-buys-44000-in-stock-93CH-4744382", "source_name": "Investing.com", "published_at": "2026-06-17T06:11:11", "published_display": "17 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) CFO Peter Mariani buys 100,000 shares in open market", "summary": "Cytosorbents Corp's CFO, Peter J. Mariani, purchased 100,000 shares of common stock at a weighted average price of $0.44 per share on June 15, 2026, increasing his direct holdings to 638,113 shares. This open-market transaction signals a positive sentiment from the insider. His h", "url": "https://www.stocktitan.net/sec-filings/CTSO/form-4-cytosorbents-corp-insider-trading-activity-a82f2eeaec29.html", "source_name": "Stock Titan", "published_at": "2026-06-16T10:39:15", "published_display": "16 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) CEO boosts stake with 261,469-share open-market buy", "summary": "Cytosorbents Corp (CTSO) CEO Phillip P. Chan increased his direct holdings by purchasing 261,469 shares in open-market transactions on June 12 and June 15, 2026. He acquired shares at weighted average prices of $0.40 and $0.43 respectively, totaling approximately $104,898. Follow", "url": "https://www.stocktitan.net/sec-filings/CTSO/form-4-cytosorbents-corp-insider-trading-activity-a060ffa02ea2.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:39:15", "published_display": "15 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents CEO Phillip Chan buys $104,897 in company stock", "summary": "Cytosorbents Corp CEO Phillip P. Chan recently purchased $104,897 worth of company stock through open market transactions on June 12 and June 15, 2026. The purchases occurred while the stock was trading near its 52-week low and is considered undervalued by InvestingPro analysis. ", "url": "https://www.investing.com/news/insider-trading-news/cytosorbents-ceo-phillip-chan-buys-104897-in-company-stock-93CH-4743520", "source_name": "Investing.com", "published_at": "2026-06-15T22:39:15", "published_display": "15 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Cytosorbents Corp (CTSO), noting its current score of 6.45, which ranks it 154 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's weak financial status and average operating efficiency. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctso/financial-health", "source_name": "TradingKey", "published_at": "2026-06-15T22:12:08", "published_display": "15 Jun 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near?", "summary": "Cytosorbents Corporation (NASDAQ:CTSO) is projected to reach breakeven by 2027, according to analysts, after incurring a final loss in 2026. This would require an average annual growth rate of 77%. The company currently has a high debt-to-equity ratio of over 2x, which poses a ri", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-ctso/cytosorbents/news/cytosorbents-corporation-nasdaqctso-is-breakeven-near-1", "source_name": "Simply Wall Street", "published_at": "2026-06-12T10:40:31", "published_display": "12 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents (NASDAQ: CTSO) asks shareholders to OK 1-for-5\u20131-for-20 reverse split", "summary": "CytoSorbents (NASDAQ: CTSO) is seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-20 at its upcoming Annual Meeting on August 13, 2026. This measure is primarily intended to help the company meet Nasdaq's minimum bid price requirement of $", "url": "https://www.stocktitan.net/sec-filings/CTSO/pre-14a-cytosorbents-corp-preliminary-proxy-statement-f7532ebc5865.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:57", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corp stock (US23283M1018): Q1 miss keeps focus on growth and cash runway", "summary": "CytoSorbents Corp reported weaker than expected Q1 2026 revenue of $8.9 million and a larger loss per share of -$0.05, missing analyst estimates. This performance keeps the focus on the company's growth trajectory, its path to profitability, and the demand for its blood purificat", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cytosorbents-corp-stock-us23283m1018-q1-miss-keeps-focus-on-growth-and/69507553", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T12:39:32", "published_display": "09 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) Edges Higher on Modest Volume, Testing Key Resistance at $0.49 - ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNbG5ReWZ1THhYWFV3c1pjMlkwMGpoUklmekNnejlFY0JGVGFkODZOMGsyVGxHMzFtN1hEMUw3RkZRVDVpc3ljV0dLYmlQQVJhYnlsaXp6dmplbm1DUXFyQnN0Y29RSlNxc2pwZzEtUkZuQVNFNll2dF83WkxsVDRCSTU5MEVkM0dTQmxrQ24wQ1k1ZVZ0Q3duSk03aHlRdC04WjE4bXg4dFg0bnF3YVNmOUVZdU54MlotS0NFUWhsT0ZSUm8?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Cytosorbents Corp (CTSO), indicating a \"Strong Sell\" consensus based on various technical indicators and moving averages. The analysis highlights that CTSO is trading below its key moving averages and identif", "url": "https://intellectia.ai/en/stock/CTSO/technical", "source_name": "Intellectia AI", "published_at": "2026-06-07T03:40:36", "published_display": "07 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-l", "summary": "CytoSorbents Corp (CTSO) shares on Nasdaq are trading at a low nominal level of USD 0.49, despite several Wall Street analysts maintaining significantly higher 12-month price targets, with a consensus of USD 5.38. The company, focused on blood purification therapies, continues to", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cytosorbents-corp-stock-us23283m1018-analyst-sentiment-and-low-share/69458659", "source_name": "Ad Hoc News", "published_at": "2026-06-01T00:51:48", "published_display": "01 Jun 2026 00:51", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO - Cytosorbents Corp Stock Price and Quote", "summary": "This article provides a comprehensive overview of Cytosorbents Corp (CTSO) stock, including its current price, financial metrics, and recent news. It details key financial data such as market cap, income, sales, and various ratios, alongside performance indicators and analyst rat", "url": "https://finviz.com/stock?t=CTSO", "source_name": "Finviz", "published_at": "2026-05-29T22:12:08", "published_display": "29 May 2026 22:12", "sentiment": "negative", "sentiment_pct": 31, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corp stock (US23283M1018): Nasdaq price action and valuation metrics in focus", "summary": "CytoSorbents Corp (CTSO) shares on the Nasdaq Capital Market continue to trade at low single-digit levels, attracting risk-tolerant investors interested in medical technology stocks. The company, which focuses on blood purification technologies, is currently assessed using revenu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cytosorbents-corp-stock-us23283m1018-nasdaq-price-action-and-valuation/69437595", "source_name": "Ad Hoc News", "published_at": "2026-05-29T01:39:16", "published_display": "29 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTSO: CytoSorbents Reports 1st Quarter Financial and Operating Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ctso-cytosorbents-reports-1st-quarter-170300618.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-05-21T17:03:00+00:00", "published_display": "21 May 2026 17:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents Earnings Call Balances Progress and Pressure", "summary": "Cytosorbents' Q1 2026 earnings call revealed a combination of cautious optimism and ongoing challenges. The company reported modest revenue growth, driven by international sales outside Germany, alongside strong margins. However, it also faced headwinds from FX losses, regulatory", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CTSO/pressreleases/2053858/cytosorbents-earnings-call-balances-progress-and-pressure/", "source_name": "The Globe and Mail", "published_at": "2026-05-20T23:10:47", "published_display": "20 May 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cytosorbents-corp-ctso-q1-2026-050246425.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T05:02:46+00:00", "published_display": "14 May 2026 05:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: CytoSorbents Q1 2026 Earnings Conference Call", "summary": "", "url": "https://finance.yahoo.com/news/transcript-cytosorbents-q1-2026-earnings-213610053.html", "source_name": "Benzinga", "published_at": "2026-05-13T21:36:10+00:00", "published_display": "13 May 2026 21:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/cytosorbents-q1-earnings-snapshot-200357687.html", "source_name": "Associated Press", "published_at": "2026-05-13T20:03:57+00:00", "published_display": "13 May 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPYzRvS014bC04bUxUc0xvYVNMYTJrWGhXUlhvYW92VklUcHpHalF0akc3allMZmxPWFRSNE02OWRlQmZCOHQ5ei1UY2xMSFdaMUROMHZyUVozQWdSVjd3TU52QTgtQVpLOUJXUFoxNTJwbDBvV1c3cTFJcGJKY2xoTi13VU1MNmFFTzc4QkhqU3VNZzJMUWV2YUtXaTNOX2xGNTR2cnZaWHl4V05iZ0xCUFFGQnpNNXNBaURhaWJtSFJoMkhNQWZFRE1WbkV0enlabHp4N3V4WDQ5a2RKMWpOa3h6S0NHc0xoUy1qbVFDMGNLLThh?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cytosorbents-report-first-quarter-2026-110000553.html", "source_name": "PR Newswire", "published_at": "2026-04-30T11:00:00+00:00", "published_display": "30 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQeTRqQ0k5TGJqUGdraFkzc0p1YWlQRUtSNFh1NFhhZjFJQ3ZpbV9TcHVObEduRlhKNUpzSGRLY1gwWGNHOTFmNktqeDRUTmp3SHZwMUVyMXVpRm5NeTlMNWhuSlFDcTFRYmN0Ykk4VEs3M3ZBalRPVHJWenhLeVVObERDTHV2NmZ2UDRxa3VQSlZKTVNTVUVtZW43b2w?oc=5", "source_name": "Market source", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cytosorbents (CTSO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1yQmtncHVOb082QkU0Z2hJVGpVNUlpTFpkN1drb3Q1aDBXNVdvMGxBUUZzd3ozNy1NM3diVTVjRW41cWlQNllPZ1E0VVdXWVZKZVRz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:06:27+00:00", "published_display": "24 Apr 2025 22:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoSorbents Corporation Announces Rights Offering Details and Stockholder Benefits", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPRDdtajNsUjlsT3FybjN5MFA2T1JkMHdkVWRXMnQ4RE9SMzZ3SEF6TWZENzFsdVBsM1NRT0V0NkNJX19TMXVDRnlQSHlYUFdvTXZOdHBzWXdYQVBmb3Y0WHhmR0doLVdPM2hSWU1iZU9odlFQblVibWVJcDRnNDU3ajFnbElSY2xjZ0REV0o3Q3hyVFJmQTlKVHR4Z2tGUnEyU0JzWjJwQ0ZYTWNfMkNHRUcyTVd3eWM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-12-09T08:00:00+00:00", "published_display": "09 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Cytosorbents (CTSO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1BNmNKaUFJUkIwVERSVXNHRUNfN2hTQk41SmhYQjg2eG9ybGxZb2R0U3BnMmFkS2ZEXzNxUHIzczV0ZFlLTl9LYTJEQXJJalI3STNOMDVnVTRDUUlYU0JaekZwZ0pPUEhQWEJfNEFLYjJVa1U2Wl9BSA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-09-03T11:11:59+00:00", "published_display": "03 Sep 2022 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 53, "sentiment_summary": {"positive": 8, "negative": 7, "neutral": 38, "score": 50, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.35, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 10.74, "count": 21}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 0.38, "latest_week": "2026-07-10", "one_week_move": -2.2, "four_week_move": -4.6, "twelve_week_move": -42.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.105705, "market_dynamics_buy_signal": false, "relative_strength": -54.993712, "fair_value_gap": -64.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.2055, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.2% over one week, -4.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 8}, {"label": "TradingKey", "count": 6}, {"label": "Zacks Small Cap Research", "count": 2}, {"label": "TradingView", "count": 2}, {"label": "Finviz", "count": 2}, {"label": "Quiver Quantitative", "count": 2}, {"label": "Donan\u0131mHaber", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 21}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.2% over one week, -4.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR\u2019s Tom Kerr, CFA"}], "updated_at": "2026-07-16T05:13:25.733053+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}